ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Mary-Ellen Taplin, Arif Hussain, Satish Shah, Neal D. Shore, Manish Agrawal, William Clark, William Jeffery Edenfield, Luke T. Nordquist, Oliver A Sartor, James E. Butrynski, Gurkamal S. Chatta, Mark T. Fleming, William K. Oh, Bill Bradley, Jessica Piel, David Nash, Gozde Colak, Jian Li, Claudia Lebedinsky, Emmanuel S. Antonarakis
Institutions: Dana-Farber Cancer Institute, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Carolina Urologic Research Center, Prisma Health, Urology Cancer Center and GU Research Network, Tulane University, Overlake Hospital Medical Center, Virginia Mason Medical Center, Virginia Oncology Associates, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, Constellation Pharmaceuticals (United States), Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4230920175